ArticleEuropean journal of drug metabolism and pharmacokinetics2026
PKPD-Based Translational Modeling of Calaspargase Pegol Preclinical Activity in Hepatocellular Carcinoma.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveCalaspargase pegol (CalPEG) is a PEGylated conjugate of L-Asparaginase (L-Asp) and an asparagine specific enzyme approved by the Food and Drug Administration (FDA) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in children and young adults. Although CalPEG is an established and effective treatment for childhood ALL, its potential in solid tumors is still underexplored. Recent reports illustrated that L-Asp may also have potential for the treatment of certain aggressive solid tumors, including hepatocellular carcinoma (HCC)[1-5]. In order to investigate this potential, clinical and preclinical data were integrated using model-informed drug development (MIDD) approaches, which are among the most adequate tools to facilitate the translation of preclinical into clinical data [6-9]. This work explores the potential of pharmacokinetic/pharmacodynamic tumor growth inhibition (PKPD TGI) modeling to maximize the use of in vivo preclinical data and PK data in patients with ALL for translation of preclinical observed antitumor activity to clinical efficacy.
methodsA PKPD TGI model was developed that described tumor volumes (TVs) versus time in a preclinical hypermethylated xenograft mouse model relevant for HCC. Translation of the PKPD TGI model to human was performed by linking the structural TGI model developed in mice with human PK model of CalPEG. This model was developed on PK data, i.e., plasma Asp activity (PAA), obtained in pediatric and adult patients with ALL and was used to predict TGI profiles of CalPEG in adult patients with HCC.
resultsThe developed PKPD TGI model adequately described the TV versus time profiles in tumor bearing (TB) mice and quantified the PKPD relationship between PAA and TGI in TB mice. The structural mouse TGI model was linked to predicted human PK parameters and this human PKPD TGI model was used to perform simulations and to predict antitumor activity of CalPEG at different doses/schedule in patients with HCC.
conclusionsThe results indicate that PKPD TGI modeling can be used to build a preclinical to clinical translational framework to predict the exposure-response relationship in patients with HCC and to inform dosing strategies or trial designs for solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.